What’s Shaping the Future of Alopecia Treatment, According to Leading Clinicians
7-Year Safety Review Confirms Brodalumab’s Steady Risk Profile in US Postmarketing Surveillance
Clinical Pearls on JAK Inhibitor Utility and Research From Eileen Cheever, MPAS, PA-C
Maria Hordinsky, MD: Early Clue in Scarring Alopecia May Change Clinical Approach